secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autonomix Medical, Inc. (AMIX)
CIK:        0001617867
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001437749-24-018924
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autonomix Medical FY2024 net loss $15.4M; cash $8.6M; topline data from first 5 patients expected June
--------------------------------------------------------------------------------

- Net loss $15.4M vs $2.0M prior year, including $8.0M non-cash warrant loss; G&A $5.2M, R&D $2.2M.
- Cash $8.6M at March 31, 2024; expects runway into Q1 2025 after $9.8M net IPO proceeds.
- IPO raised $11.2M gross ($9.8M net) via 2,234,222 shares at $5.00 each.
- PoC human clinical study for pancreatic cancer pain ongoing; topline data from first 5 patients expected in June 2024.
- Preclinical study showed statistically significant reduction in metastases and tumor mass with targeted nerve ablation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924018924/0001437749-24-018924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924018924/amix20240531_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-018924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer